8-K: Cidara Therapeutics Finalizes 2023 Executive Bonuses and Discloses Pay Versus Performance

Cidara Therapeutics has announced the finalization of 2023 executive bonuses and provided a revised summary compensation table, including pay versus performance details.

Summary

• Cidara Therapeutics' Board of Directors finalized the 2023 annual bonus amounts for named executive officers on May 14, 2024.
• These bonus amounts were not available when the company filed its 2023 Form 10-K on April 22, 2024.
• The company has provided a revised Summary Compensation Table and Pay Versus Performance Tables to include this information.
• The total compensation for CEO Jeffrey Stein in 2023 was $1,558,544, including a bonus of $292,100.
• Chief Medical Officer Taylor Sandison received total compensation of $884,092, with a bonus of $167,600.
• Chief Operating Officer Shane Ward's total compensation was $929,855, including a bonus of $156,400.
• The compensation actually paid to the CEO was calculated as $1,601,757, which differs from the total compensation due to adjustments for equity awards.
• The average compensation actually paid to non-CEO named executive officers was $907,897.
• The company's net loss for 2023 was $22,931,000.
• A $100 investment in Cidara on December 31, 2020, would have been worth $39.70 by the end of 2023 based on total stockholder return.

Sentiment

Score: 3

Explanation: The document reveals a significant net loss and poor stockholder return, which are negative indicators. While the disclosure is transparent, the overall financial performance is concerning.

Positives

• The company has provided detailed information on executive compensation and pay versus performance.
• The disclosure includes a breakdown of how compensation actually paid is calculated, providing transparency.

Negatives

• The company reported a net loss of $22.931 million for 2023.
• The total stockholder return on a $100 investment since 2020 has significantly decreased to $39.70 by the end of 2023.

Risks

• The company's significant net loss in 2023 could raise concerns about its financial stability.
• The low total stockholder return indicates potential challenges in generating value for investors.

Industry Context

This announcement is typical for publicly traded companies, providing transparency on executive compensation and performance. The pay versus performance disclosure is a regulatory requirement.

Comparison to Industry Standards

• Executive compensation packages vary widely across the biotechnology industry, depending on company size, stage of development, and financial performance.
• Companies like Gilead Sciences, Amgen, and Regeneron, which are larger and more established, typically have higher executive compensation packages.
• Cidara's compensation structure is likely more aligned with smaller, development-stage biotech companies.
• The negative total stockholder return is concerning and may be worse than industry averages, especially for companies that have been publicly traded for several years.
• The net loss is not unusual for a development-stage biotech company, but the magnitude of the loss is significant.

Stakeholder Impact

• Shareholders may be concerned about the company's financial performance and the low total stockholder return.
• Employees may be impacted by the company's financial situation, potentially affecting job security or future compensation.
• Creditors may be more cautious about lending to the company given the reported net loss.

Key Dates

Keywords

executive compensation, bonus, pay versus performance, stock awards, option awards, net loss, total stockholder return, financial results, Cidara Therapeutics